From: Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris
Company | Drug | Formulation | Effect | Mechanism | Stage |
---|---|---|---|---|---|
Melinta Therapeutics | Radezolid | Topical oxazolidnone | Antibacterial | Second generation antibiotic with enhanced ribosomal binding | Phase II |
Allergan and Paratek Pharmaceuticals | Seysara® | Oral sarecycline antibiotic | Antibacterial and anti-inflammatory | Narrow spectrum of activity against C. acnes and S. aureus | Phase III |
Novartis | CJM112 | Â | Anti-inflammatory | Anti-IL-17 | Phase II |
Sebacia | Microparticles | Topical suspension of gold microparticles | Sebostatic | Photothermolysis of sebaceous glands | Phase III |
KLOX Technologies | Kleresca® | Cream containing chromophores | Killing of C. acnes | Excitation of bacterial porphyrins by light absorption | FDA-approved |
Botanix | BTX 1503 | Transdermal gel containing synthetic cannabidiol | Anti-inflammatory and sebostatic | Activation of vanilloid-4 ion channels to inhibit sebocyte lipogenesis | Phase Ib |
Foamix Pharmaceuticals | FMX101 | Topical minocycline foam (4%) | Antibacterial, anti-inflammatory, and antioxidant | Blocks inflammasome-pyroptosis and cleaved IL-1β | Phase III |
BiophramaX | BPX-01 | Solubilized topical minocycline gel | Antibacterial, anti-inflammatory, and antioxidant | Inhibits protein synthesis in bacteria and inhibits iNOS and MMPs in cells | Phase III |
Dermira | Olumacostat glasaretil (DRM01) | Topical small molecule prodrug | Sebostatic | Inhibitor of acetyl coenzyme A (CoA) carboxylase involved in FA biosynthesis | Phase III |
Allergan | ANT-1207 | Topical botulinum toxin type A | Anti-inflammatory | Acetylcholine inhibitors and glutamate-antagonists | Phase II |
Promius Pharma LLC | DFD-03 | Topical tazarotene lotion | Anti-inflammatory | Retinoid prodrug: suppress keratinocyte hyperproliferation | Phase III |
Celtaxsys | Acebilustat (CTX-4430) | Oral capsule | Anti-inflammatory | Leukotriene A4 hydrolase inhibitors | Phase II |
AOBiome | B244 | Topical spray | Anti-inflammatory and microbiome modulation | Production of nitrite and NO to suppress inflammation | Phase IIb |
Novan Thereputics | SB204 | Topical gel | Antibacterial and anti-inflammatory | Release of NO that inhibits IL-1β | Phase III |
AndroScience | ASC-J9 | Topical cream | Androgen modulation | Synthetic androgen receptor degradation enhancer | Phase III |
Galderma | Trifarotene (CD-5789) | Topical cream | Anti-inflammatory | Retinoic acid receptor gamma agonists | Phase III |
Seoul National University Hospital | Lupeol | Topical lupeol cream | Suppressed lipogenesis, anti-inflammatory | NF-κB and PI3K/Akt Modulator | In clinical trials |
Sienna Biopharmaceuticals | SNA-001 | Topical silver particle suspension | Photothermolysis of sebaceous gland | Laser-excited particles that convert light energy to heat | Phase IIb |